These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

139 related items for PubMed ID: 2947679

  • 1. Phase I studies with trimetrexate: clinical pharmacology, analytical methodology, and pharmacokinetics.
    Lin JT, Cashmore AR, Baker M, Dreyer RN, Ernstoff M, Marsh JC, Bertino JR, Whitfield LR, Delap R, Grillo-Lopez A.
    Cancer Res; 1987 Jan 15; 47(2):609-16. PubMed ID: 2947679
    [Abstract] [Full Text] [Related]

  • 2. Pediatric phase I trial and pharmacokinetic study of trimetrexate.
    Balis FM, Patel R, Luks E, Doherty KM, Holcenberg JS, Tan C, Reaman GH, Belasco J, Ettinger LJ, Zimm S.
    Cancer Res; 1987 Sep 15; 47(18):4973-6. PubMed ID: 2957048
    [Abstract] [Full Text] [Related]

  • 3. Phase I clinical and pharmacokinetic study of trimetrexate using a daily x5 schedule.
    Stewart JA, McCormack JJ, Tong W, Low JB, Roberts JD, Blow A, Whitfield LR, Haugh LD, Grove WR, Lopez AJ.
    Cancer Res; 1988 Sep 01; 48(17):5029-35. PubMed ID: 2970294
    [Abstract] [Full Text] [Related]

  • 4. Pharmacology and toxicity of a potent "nonclassical" 2,4-diamino quinazoline folate antagonist, trimetrexate, in normal dogs.
    Weir EC, Cashmore AR, Dreyer RN, Graham ML, Hsiao N, Moroson BA, Sawicki WL, Bertino JR.
    Cancer Res; 1982 May 01; 42(5):1696-702. PubMed ID: 6461409
    [Abstract] [Full Text] [Related]

  • 5. Pharmacokinetics of trimetrexate administered by five-day continuous infusion to patients with advanced cancer.
    Reece PA, Morris RG, Bishop JF, Olver IN, Raghavan D.
    Cancer Res; 1987 Jun 01; 47(11):2996-9. PubMed ID: 2952262
    [Abstract] [Full Text] [Related]

  • 6. Phase I evaluation and pharmacokinetic study of pyrazine-2-diazohydroxide administered as a single bolus intravenous injection in patients with advanced solid tumors.
    Supko JG, Balcerzak SP, Kraut EH.
    Cancer Res; 1993 Oct 15; 53(20):4843-9. PubMed ID: 8402671
    [Abstract] [Full Text] [Related]

  • 7. Phase I and clinical pharmacology study of trimetrexate administered weekly for three weeks.
    Fanucchi MP, Walsh TD, Fleisher M, Lokos G, Williams L, Cassidy C, Vidal P, Chou TC, Niedzwiecki D, Young CW.
    Cancer Res; 1987 Jun 15; 47(12):3303-8. PubMed ID: 2953412
    [Abstract] [Full Text] [Related]

  • 8. Phase I and pharmacokinetic study of triapine, a potent ribonucleotide reductase inhibitor, administered daily for five days in patients with advanced solid tumors.
    Murren J, Modiano M, Clairmont C, Lambert P, Savaraj N, Doyle T, Sznol M.
    Clin Cancer Res; 2003 Sep 15; 9(11):4092-100. PubMed ID: 14519631
    [Abstract] [Full Text] [Related]

  • 9. [Phase I study of raltitrexed (ZD-1694)].
    Horikoshi N, Aiba K, Fukuoka M, Akazawa S, Sakata Y, Furuse K, Kanamaru R, Kudoh S, Konishi T, Kurihara M, Niitani H, Furue H, Tsukagoshi S, Taguchi T, Yoshida S, Ota K, Kotake T, Wakui A.
    Gan To Kagaku Ryoho; 1998 Nov 15; 25(13):2075-84. PubMed ID: 9838910
    [Abstract] [Full Text] [Related]

  • 10. A phase I and pharmacokinetic study of melphalan using a 24-hour continuous infusion in patients with advanced malignancies.
    Pinguet F, Culine S, Bressolle F, Astre C, Serre MP, Chevillard C, Fabbro M.
    Clin Cancer Res; 2000 Jan 15; 6(1):57-63. PubMed ID: 10656432
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Pharmacokinetic study of trimetrexate in combination with cisplatin.
    Hudes GR, LaCreta F, Walczak J, Tinsley P, Litwin S, Comis RL, O'Dwyer PJ.
    Cancer Res; 1991 Jun 15; 51(12):3080-7. PubMed ID: 1828188
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. A phase I, first in man study of OSI-7836 in patients with advanced refractory solid tumors: IND.147, a study of the Investigational New Drug Program of the National Cancer Institute of Canada Clinical Trials Group.
    Goss G, Siu LL, Gauthier I, Chen EX, Oza AM, Goel R, Maroun J, Powers J, Walsh W, Maclean M, Drolet DW, Rusk J, Seymour LK, Investigational New Drug Program of the National Cancer Institute of Canada Clinical Trials Group.
    Cancer Chemother Pharmacol; 2006 Nov 15; 58(5):703-10. PubMed ID: 16528532
    [Abstract] [Full Text] [Related]

  • 15. [Phase I study of CI-898. CI-898 Study Group].
    Taguchi T, Tsukagoshi S, Furue H, Niitani H, Ohta K, Ariyoshi H, Hasegawa K, Majima H, Nakao I, Yasutomi M.
    Gan To Kagaku Ryoho; 1991 Aug 15; 18(10):1599-612. PubMed ID: 1831340
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. A phase I and pharmacokinetic study of 1843U89, a noncompetitive inhibitor of thymidylate synthase, in patients with advanced solid malignancies.
    Schwartz G, Johnson TR, Goetz A, Burris H, Smetzer L, Lampkin T, Sailstad J, Hohneker JA, Von Hoff DD, Rowinsky EK.
    Clin Cancer Res; 2001 Jul 15; 7(7):1901-11. PubMed ID: 11448903
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Phase I clinical and pharmacokinetic study of plitidepsin as a 1-hour weekly intravenous infusion in patients with advanced solid tumors.
    Izquierdo MA, Bowman A, García M, Jodrell D, Martinez M, Pardo B, Gómez J, López-Martin JA, Jimeno J, Germá JR, Smyth JF.
    Clin Cancer Res; 2008 May 15; 14(10):3105-12. PubMed ID: 18483378
    [Abstract] [Full Text] [Related]

  • 20. Dose escalation and pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in children with solid tumors: a pediatric oncology group study.
    Marina NM, Cochrane D, Harney E, Zomorodi K, Blaney S, Winick N, Bernstein M, Link MP.
    Clin Cancer Res; 2002 Feb 15; 8(2):413-8. PubMed ID: 11839657
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.